$ Value
—
Shares
50,000
Price
—
Filed
Apr 17
Insider
Name
Stazzone Peter
Title
Chief Financial Officer
CIK
0002083297
Roles
Transaction Details
Transaction Date
2026-04-15
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
50,000
Footnotes
On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 50,000 options (the "Options") granted to the Reporting Person on September 1, 2025. In exchange for the Options, the Reporting Person received 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vest immediately upon grant. | The canceled Options provided for vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026.
Filing Info
Stazzone Peter's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-15 | LIXT | A | — |
| 2026-04-15 | LIXT | D | — |
| 2025-09-01 | LIXT | A | $0 |
Other Insiders at LIXT (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Felix Lourdes | — | — | 2026-04-15 |
|
Pursglove Geordan Garrett
CEO and Chairman of the Board
|
— | — | 2026-04-15 |
| Sawyer Jason David | — | — | 2026-04-15 |
| Holloway Michael Andrew | — | — | 2026-04-15 |
|
Stazzone Peter
Chief Financial Officer
|
— | — | 2026-04-15 |
| Primus Guy Warren | — | — | 2026-04-15 |